financetom
Business
financetom
/
Business
/
Nu Holdings Shares Are Falling Today: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nu Holdings Shares Are Falling Today: What's Going On?
Feb 21, 2025 9:25 AM

Nu Holdings Ltd. ( NU ) shares are trading lower following the company's fourth-quarter revenue miss.

What To Know: The digital banking company reported fourth-quarter revenue of $2.99 billion, falling short of analyst estimates of $3.29 billion. Earnings per share came in at 11 cents, matching expectations.

Despite the revenue miss, Nu Holdings ( NU ) continued to expand its customer base, adding 4.5 million new users in fourth-quarter, bringing its total to 114.2 million, a 22% increase year-over-year. The company also became the third-largest financial institution in Brazil by customer count. CEO David Vélez highlighted advancements in the company's high-income strategy in Brazil, as well as growth in Mexico and new offerings like NuCel and NuTravel.

Nu's interest-earning portfolio reached $11.2 billion by the end of the quarter, with its credit card portfolio growing 28% year-over-year and total deposits surging 55%. However, the revenue miss overshadowed these growth metrics, leading to the stock’s sharp decline.

NU Price Action: Nu Holdings ( NU ) shares were down 15.7% at $11.25 at the time of writing, according to Benzinga Pro.

Read Next:

US Services Drop Sharply: ‘Darkening Picture’ Of High Prices, Uncertainty, Economist Says

Image Via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Masimo Says US FDA Clears Masimo W1 Medical Watch Connectivity With SafetyNet Telemonitoring System
Masimo Says US FDA Clears Masimo W1 Medical Watch Connectivity With SafetyNet Telemonitoring System
Aug 12, 2024
08:35 AM EDT, 08/12/2024 (MT Newswires) -- Masimo ( MASI ) said Monday its Masimo W1 medical watch has received the US Food and Drug Administration's clearance to integrate it with the Masimo SafetyNet comprehensive telemonitoring solution. The integration provides improved patient data through the wrist, which will be available on the Masimo SafetyNet smartphone app and its web-based clinician...
Revance Therapeutics to Be Acquired by Crown Laboratories for $924 Million
Revance Therapeutics to Be Acquired by Crown Laboratories for $924 Million
Aug 12, 2024
08:35 AM EDT, 08/12/2024 (MT Newswires) -- Revance Therapeutics ( RVNC ) has agreed to be acquired by Crown Laboratories for $924 million, the companies said Monday. Under their merger agreement, Crown will make a tender offer to acquire all outstanding Revance shares for $6.66 each, an 89% premium to Friday's close, according to the companies. They said Revance's board...
Brazilian airline Azul lowers 2024 earnings and capacity forecasts
Brazilian airline Azul lowers 2024 earnings and capacity forecasts
Aug 12, 2024
SAO PAULO, Aug 12 (Reuters) - Brazilian airline Azul ( AZUL ) reduced its estimate for 2024 core earnings on Monday while bumping up its leverage forecast in the face of slower than previously expected capacity growth and weakness of Brazil's currency. Azul ( AZUL ) now expects earnings before interest, tax, depreciation and amortization (EBITDA) to be more than...
Ascendis Pharma's hormone disorder therapy gets US approval
Ascendis Pharma's hormone disorder therapy gets US approval
Aug 12, 2024
By Sneha S K and Sriparna Roy Aug 12 (Reuters) - Ascendis Pharma ( ASND ) said on Monday the U.S. Food & Drug Administration had approved its therapy to treat adult patients with a hormone disorder, sending the Danish drugmaker's shares more than 10% higher in premarket trading. Ascendis's Yorvipath, will become the only approved treatment for the condition,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved